Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 870

1.

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.

van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW.

Eur J Nucl Med Mol Imaging. 2019 Nov 9. doi: 10.1007/s00259-019-04555-6. [Epub ahead of print]

PMID:
31705176
2.

When is off-label off-road?

de Vries EGE, Cherny NI, Voest EE.

Ann Oncol. 2019 Oct 1;30(10):1536-1538. doi: 10.1093/annonc/mdz445. No abstract available.

PMID:
31688929
3.

Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans.

van der Veen EL, Antunes IF, Maarsingh P, Hessels-Scheper J, Zijlma R, Boersma HH, Jorritsma-Smit A, Hospers GAP, de Vries EGE, Lub-de Hooge MN, de Vries EFJ.

EJNMMI Radiopharm Chem. 2019 Jul 17;4(1):15. doi: 10.1186/s41181-019-0062-7.

4.

Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit.

Dafni U, Cherny NI, de Vries EGE.

JAMA Oncol. 2019 Oct 17. doi: 10.1001/jamaoncol.2019.4091. [Epub ahead of print] No abstract available.

PMID:
31621808
5.

Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors.

van Faassen M, Bouma G, de Hosson LD, Peters MAM, Kats-Ugurlu G, de Vries EGE, Walenkamp AME, Kema IP.

Clin Chem. 2019 Nov;65(11):1388-1396. doi: 10.1373/clinchem.2019.305359. Epub 2019 Sep 24.

PMID:
31551315
6.

Quantitative fluorescence endoscopy: an innovative endoscopy approach to evaluate neoadjuvant treatment response in locally advanced rectal cancer.

Tjalma JJJ, Koller M, Linssen MD, Hartmans E, de Jongh S, Jorritsma-Smit A, Karrenbeld A, de Vries EG, Kleibeuker JH, Pennings JP, Havenga K, Hemmer PH, Hospers GA, van Etten B, Ntziachristos V, van Dam GM, Robinson DJ, Nagengast WB.

Gut. 2019 Sep 18. pii: gutjnl-2019-319755. doi: 10.1136/gutjnl-2019-319755. [Epub ahead of print] No abstract available.

7.

Use of selective serotonin reuptake inhibitors is associated with very low plasma-free serotonin concentrations in humans.

Peters MA, van Faassen M, de Jong WH, Bouma G, Meijer C, Walenkamp AM, de Vries EG, Oosting SF, Ruhé HG, Kema IP.

Ann Clin Biochem. 2019 Oct 10:4563219880567. doi: 10.1177/0004563219880567. [Epub ahead of print] No abstract available.

PMID:
31533444
8.

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers.

Peters MAM, Meijer C, Fehrmann RSN, Walenkamp AME, Kema IP, de Vries EGE, Hollema H, Oosting SF.

Pathol Oncol Res. 2019 Sep 2. doi: 10.1007/s12253-019-00734-w. [Epub ahead of print]

PMID:
31478179
9.

Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1.

Timaner M, Kotsofruk R, Raviv Z, Magidey K, Shechter D, Kan T, Nevelsky A, Daniel S, de Vries EGE, Zhang T, Kaidar-Person O, Kerbel RS, Shaked Y.

Oncogene. 2019 Aug 29. doi: 10.1038/s41388-019-0971-7. [Epub ahead of print]

PMID:
31467431
10.

Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity.

Heijink AM, Everts M, Honeywell ME, Richards R, Kok YP, de Vries EGE, Lee MJ, van Vugt MATM.

Cell Rep. 2019 Aug 27;28(9):2345-2357.e5. doi: 10.1016/j.celrep.2019.07.070.

11.

Sulfonylurea derivatives and cancer, friend or foe?

Hendriks AM, Schrijnders D, Kleefstra N, de Vries EGE, Bilo HJG, Jalving M, Landman GWD.

Eur J Pharmacol. 2019 Oct 15;861:172598. doi: 10.1016/j.ejphar.2019.172598. Epub 2019 Aug 10. Review.

12.

Melatonin is not stored in platelets.

van Faassen M, Peters MAM, Walenkamp AM, de Vries EGE, Oosting SF, Kema IP.

Clin Chim Acta. 2019 Nov;498:17-20. doi: 10.1016/j.cca.2019.07.028. Epub 2019 Jul 26.

PMID:
31356792
13.

RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.

van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, Radema SA, van Herpen CML, de Groot DJA, de Vries EGE, Jansen MPHM, Sleijfer S, Verheul HMW.

Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30.

14.

Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.

van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP.

Am J Surg Pathol. 2019 Oct;43(10):1355-1360. doi: 10.1097/PAS.0000000000001321.

PMID:
31283631
15.

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.

de Hosson LD, van der Loo-van der Schaaf AM, Boellaard R, van Snick JH, de Vries EGE, Brouwers AH, Walenkamp AME.

Clin Nucl Med. 2019 Aug;44(8):612-619. doi: 10.1097/RLU.0000000000002640.

PMID:
31274606
16.

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P.

Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27.

PMID:
31257177
17.

Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis.

Jauw YWS, Bensch F, Brouwers AH, Hoekstra OS, Zijlstra JM, Pieplenbosch S, Schröder CP, Zweegman S, van Dongen GAMS, Menke-van der Houven van Oordt CW, de Vries EGE, de Vet HCW, Boellaard R, Huisman MC.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1840-1849. doi: 10.1007/s00259-019-04377-6. Epub 2019 Jun 17.

18.

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.

de Hosson LD, van der Loo-van der Schaaf AM, Boellaard R, van Snick JH, de Vries EGE, Brouwers AH, Walenkamp AME.

Clin Nucl Med. 2019 Jun 13. doi: 10.1097/RLU.0000000000002640. [Epub ahead of print]

PMID:
31205146
19.

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6.

20.

Consideration of breast cancer subtype in targeting the androgen receptor.

Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP, Schröder CP, Fehrmann RSN, de Vries EGE.

Pharmacol Ther. 2019 Aug;200:135-147. doi: 10.1016/j.pharmthera.2019.05.005. Epub 2019 May 8. Review.

21.

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.

Suurs FV, Lub-de Hooge MN, de Vries EGE, de Groot DJA.

Pharmacol Ther. 2019 Sep;201:103-119. doi: 10.1016/j.pharmthera.2019.04.006. Epub 2019 Apr 24. Review.

22.

Shortages of inexpensive essential medicines.

Vyas M, de Vries EGE, Casali PG, Tabernero J.

Lancet Oncol. 2019 May;20(5):e224-e225. doi: 10.1016/S1470-2045(19)30248-7. Epub 2019 Apr 18. No abstract available.

PMID:
31006527
23.

MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.

Stutvoet TS, Kol A, de Vries EG, de Bruyn M, Fehrmann RS, Terwisscha van Scheltinga AG, de Jong S.

J Pathol. 2019 Sep;249(1):52-64. doi: 10.1002/path.5280. Epub 2019 May 21.

24.

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology.

Giuliani R, Tabernero J, Cardoso F, McGregor KH, Vyas M, de Vries EGE.

ESMO Open. 2019 Mar 6;4(2):e000460. doi: 10.1136/esmoopen-2018-000460. eCollection 2019.

25.

Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree.

Cherny NI, de Vries EGE, Schilsky RL.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):xxi. doi: 10.6004/jnccn.2019.7293. No abstract available.

PMID:
30959465
26.

ESMO-MCBS: setting the record straight.

Cherny NI, Tabernero J, de Vries EGE.

Lancet Oncol. 2019 Apr;20(4):e192. doi: 10.1016/S1470-2045(19)30174-3. No abstract available.

PMID:
30942179
27.

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.

Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group.

J Clin Oncol. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12.

PMID:
30860949
28.

Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial.

de Hosson LD, Bouma G, Stelwagen J, van Essen H, de Bock GH, de Groot DJA, de Vries EGE, Walenkamp AME.

Orphanet J Rare Dis. 2019 Feb 28;14(1):60. doi: 10.1186/s13023-019-1035-3.

29.

8O89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors.

Giesen D, Broer LN, Lub-De Hooge MN, Popova I, Howng B, Vasiljeva O, de Vries EGE, Pool M.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz029.001. doi: 10.1093/annonc/mdz029.001. No abstract available.

PMID:
30810205
30.

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake.

Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJA, de Vries EGE.

Clin Cancer Res. 2019 Jun 15;25(12):3517-3527. doi: 10.1158/1078-0432.CCR-18-2918. Epub 2019 Feb 11.

PMID:
30745297
31.

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Wind TT, Jalving M, de Haan JJ, de Vries EGE, van Vugt MATM, Reijngoud DJ, van Rijn RS, Haanen JBAG, Blank CU, Hospers GAP, Fehrmann RSN.

Oncoimmunology. 2019 Jan 3;8(3):1558664. doi: 10.1080/2162402X.2018.1558664. eCollection 2019.

32.

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.

Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL.

J Clin Oncol. 2019 Feb 1;37(4):336-349. doi: 10.1200/JCO.18.00729. Epub 2018 Dec 17.

PMID:
30707056
33.

Friction in the contact between skin and a soft counter material: Effects of hardness and surface finish.

Klaassen M, de Vries EG, Masen MA.

J Mech Behav Biomed Mater. 2019 Apr;92:137-143. doi: 10.1016/j.jmbbm.2019.01.006. Epub 2019 Jan 10.

PMID:
30685727
34.

Integrating molecular nuclear imaging in clinical research to improve anticancer therapy.

de Vries EGE, Kist de Ruijter L, Lub-de Hooge MN, Dierckx RA, Elias SG, Oosting SF.

Nat Rev Clin Oncol. 2019 Apr;16(4):241-255. doi: 10.1038/s41571-018-0123-y. Review.

PMID:
30479378
35.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE.

Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.

PMID:
30478423
36.

Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis.

de Heer EC, Brouwers AH, Boellaard R, Sluiter WJ, Diercks GFH, Hospers GAP, de Vries EGE, Jalving M.

EJNMMI Res. 2018 Nov 20;8(1):101. doi: 10.1186/s13550-018-0453-x.

37.

Molecular imaging to enlighten cancer immunotherapies and underlying involved processes.

van der Veen EL, Bensch F, Glaudemans AWJM, Lub-de Hooge MN, de Vries EGE.

Cancer Treat Rev. 2018 Nov;70:232-244. doi: 10.1016/j.ctrv.2018.09.007. Epub 2018 Sep 25. Review.

PMID:
30308466
38.

Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.

de Boer HR, Pool M, Joosten E, Everts M, Samplonius DF, Helfrich W, Groen HJM, van Cooten S, Fusetti F, Fehrmann RSN, de Vries EGE, van Vugt MATM.

Oncogene. 2019 Feb;38(9):1477-1488. doi: 10.1038/s41388-018-0522-7. Epub 2018 Oct 10.

PMID:
30305724
39.

Preparing for the incoming wave of biosimilars in oncology.

Wolff-Holz E, Garcia Burgos J, Giuliani R, Befrits G, de Munter J, Avedano L, Aitken M, Gonzalez-Quevedo R, Vyas M, de Vries EGE, Tabernero J.

ESMO Open. 2018 Sep 5;3(6):e000420. doi: 10.1136/esmoopen-2018-000420. eCollection 2018. Erratum in: ESMO Open. 2018 Oct 14;3(6):e000420corr1.

40.

Tumor-associated macrophages in breast cancer: Innocent bystander or important player?

Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP.

Cancer Treat Rev. 2018 Nov;70:178-189. doi: 10.1016/j.ctrv.2018.08.010. Epub 2018 Aug 28. Review.

41.

Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse.

Bensch F, Smeenk MM, van Es SC, de Jong JR, Schröder CP, Oosting SF, Lub-de Hooge MN, Menke-van der Houven van Oordt CW, Brouwers AH, Boellaard R, de Vries EGE.

Theranostics. 2018 Jul 30;8(16):4295-4304. doi: 10.7150/thno.26370. eCollection 2018.

42.

Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer.

van Rooijen JM, Qiu SQ, Timmer-Bosscha H, van der Vegt B, Boers JE, Schröder CP, de Vries EGE.

Eur J Cancer. 2018 Nov;103:52-60. doi: 10.1016/j.ejca.2018.08.001. Epub 2018 Sep 9.

PMID:
30208359
43.

Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer.

Bense RD, Qiu SQ, de Vries EGE, Schröder CP, Fehrmann RSN.

Cancer Treat Rev. 2018 Nov;70:118-126. doi: 10.1016/j.ctrv.2018.07.015. Epub 2018 Jul 26. Review.

44.

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework.

Cherny NI, de Vries EGE; European Society for Medical Oncology Magnitude of Clinical Benefit Scale Working Group.

JAMA Oncol. 2018 Oct 1;4(10):1437. doi: 10.1001/jamaoncol.2018.3264. No abstract available.

PMID:
30128567
45.

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.

Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2300-2306. doi: 10.1007/s00259-018-4099-8. Epub 2018 Jul 30.

46.

Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.

Brahm CG, den Hollander MW, Enting RH, de Groot JC, Solouki AM, den Dunnen WFA, Heesters MAAM, Wagemakers M, Verheul HMW, de Vries EGE, Pruim J, Walenkamp AME.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2404-2412. doi: 10.1007/s00259-018-4090-4. Epub 2018 Jul 21.

47.

Micro-computed tomography (micro-CT) for intraoperative surgical margin assessment of breast cancer: A feasibility study in breast conserving surgery.

Qiu SQ, Dorrius MD, de Jongh SJ, Jansen L, de Vries J, Schröder CP, Zhang GJ, de Vries EGE, van der Vegt B, van Dam GM.

Eur J Surg Oncol. 2018 Nov;44(11):1708-1713. doi: 10.1016/j.ejso.2018.06.022. Epub 2018 Jul 3.

PMID:
30005963
48.

Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors.

Waaijer SJH, Warnders FJ, Stienen S, Friedrich M, Sternjak A, Cheung HK, van Scheltinga AGTT, Schröder CP, de Vries EGE, Lub-de Hooge MN.

Clin Cancer Res. 2018 Oct 15;24(20):4988-4996. doi: 10.1158/1078-0432.CCR-18-0786. Epub 2018 Jul 6.

49.

Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database.

Moek KL, Fehrmann RSN, van der Vegt B, de Vries EGE, de Groot DJA.

Am J Pathol. 2018 Sep;188(9):1973-1981. doi: 10.1016/j.ajpath.2018.05.014. Epub 2018 Jun 21.

PMID:
29935166
50.

Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al.

Cherny NI, Dafni U, Piccart M, Latino NJ, Douillard JY, Bogaerts J, Karlis D, Zygoura P, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE.

Ann Oncol. 2018 May 1;29(5):1335-1338. doi: 10.1093/annonc/mdy108. No abstract available.

PMID:
29659680

Supplemental Content

Loading ...
Support Center